SERA
Sera Prognostics IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$86.90M
P/E Ratio
—
EPS
$-0.67
Beta
1.06
52W High
$4.09
52W Low
$1.37
50-Day MA
$2.29
200-Day MA
$2.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Sera Prognostics Inc
Sera Prognostics Inc. is a pioneering healthcare company focused on advancing maternal-fetal health through innovative diagnostic solutions. Leveraging its proprietary biomarker platform, Sera developed the PreTRM test to assess the risk of preterm birth, enabling timely clinical interventions that can significantly improve pregnancy outcomes. With a strong emphasis on collaboration with healthcare providers, Sera is poised to lead the prenatal diagnostics market, enhancing both maternal health and overall societal well-being. The company's dedication to innovation not only aims to foster healthier pregnancies but also seeks to generate long-term value for its investors.
Fundamentals
| Revenue (TTM) | 81,000 |
| Gross Profit (TTM) | -83,000 |
| EBITDA | $-35.68M |
| Operating Margin | -89540.00% |
| Return on Equity | -51.80% |
| Return on Assets | -26.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.94 |
| Price-to-Book | 1.04 |
| Price-to-Sales (TTM) | 1072.83 |
| EV/Revenue | 511.91 |
| EV/EBITDA | -0.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -58.30% |
| Shares Outstanding | $38.18M |
| Float | $27.41M |
| % Insiders | 10.99% |
| % Institutions | 57.05% |
Analyst Ratings
Consensus ($5.00 target)
3
BuyData last updated: 4/9/2026